拜耳利伐沙班片的功效与作用

(Rivaroxaban) is the world's first clinically applied inhibitor that directly acts on coagulation factor Xa. It was jointly developed by Bayer Pharmaceuticals of Germany and Johnson & Johnson of the United States. In the study of rivaroxaban, it was found that the degree of inhibition of factor Xa and factor IIa, the prolongation of APTT, and the prolongation of PT were positively correlated with the dose, indicating that the pharmacodynamics of rivaroxaban are predictable; at the same time, the drug does not require routine monitoring of coagulation function and routine dose adjustment, so it can improve patients' medication compliance.

Compared with other traditional drugs, Bayer's rivaroxaban tablets have the characteristics of high bioavailability, accurate efficacy, good safety, easy use, and no need for frequent monitoring of coagulation indicators. However, rivaroxaban also has certain shortcomings, such as the lack of specific antagonists to reverse the anticoagulant effect in the event of severe bleeding. Because the pharmacokinetic mechanism of rivaroxaban is clear, there is no need to adjust the dose based on laboratory indicators during clinical use, which may lead to undertreatment or overdose.

Bayer, founded in Germany in 1863, is one of the world's largest chemical and pharmaceutical companies. Bayer's slogan is "making life full of vitality with innovative technology", and the company's goals are environmental protection, safety, quality and efficiency. The many corporate social responsibility projects implemented by Bayer are not only social responsibilities in the traditional sense, but also innovative corporate social responsibilities. Through systemic changes, they guide themselves and society towards the goal of sustainable development.

The absorption of rivaroxaban depends on the site of drug release in the gastrointestinal tract, and administration of rivaroxaban in the distal stomach should be avoided. Relevant foreign studies have shown that the area under the receiver operating characteristic curve (AUC) and Cmax of rivaroxaban are dose-dependent, and subjects did not experience accumulation effects at any dose, indicating that it has high safety and tolerability in a large dose range among healthy people. In this regard, patients can purchase and use this medicine with confidence.

Recommended hot articles: /newsDetail/97115.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.